Form 4: Eledon Director Allan Kirk Converts 3,430 RSUs to Common Stock

Eledon Pharmaceuticals Director Allan Kirk converted 3,430 restricted stock units into common stock on January 10, 2026, increasing his direct beneficial ownership.

Summary

• Allan Kirk, a Director of Eledon Pharmaceuticals, Inc. (ELDN), acquired 3,430 shares of common stock.
• The acquisition resulted from the settlement of restricted stock units (RSUs) on a one-for-one basis.
• The RSUs were granted on January 10, 2025, and vested 100% on January 10, 2026.
• The transaction price for the acquisition was $0, as it represents the conversion of previously granted equity awards.
• Following this transaction, Allan Kirk directly beneficially owns 3,430 shares of common stock.

Sentiment

Score: 7

Explanation: The transaction is a positive indicator of director ownership and the execution of a standard equity compensation plan, aligning director interests with shareholders. It is a routine event, so the positive impact is moderate.

Positives

• Allan Kirk, a Director, increased his direct beneficial ownership in Eledon Pharmaceuticals by 3,430 shares.
• The vesting and conversion of restricted stock units demonstrate the execution of the company's equity compensation plan.

Negatives

• No negative aspects are indicated by this routine insider transaction report.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider transactions, such as the vesting and conversion of restricted stock units, are common in the biotechnology and pharmaceutical industries as a form of executive and director compensation. They align the interests of management with shareholders by providing equity ownership.

Comparison to Industry Standards

• This transaction is a standard equity compensation event, consistent with practices across publicly traded companies, particularly in the biotech sector where long-term incentives are crucial for retaining talent. No specific comparable companies or projects are relevant for this routine Form 4 filing.

Related Party Transactions

• This filing details an insider transaction related to equity compensation, which is a common form of related party dealing in public companies. The transaction involves the conversion of restricted stock units granted to a director.

Stakeholder Impact

• Shareholders: Positive, as it indicates a director's increased direct ownership, aligning their interests with other shareholders. It also reflects the normal operation of the company's equity compensation plan.
• Employees: Not directly impacted by this specific director transaction, but it reflects the broader use of equity compensation.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the completion of this transaction.

Key Dates

Keywords

Eledon Pharmaceuticals, ELDN, Allan Kirk, Director, Form 4, Insider Transaction, Restricted Stock Units, RSU, Common Stock, Beneficial Ownership, Equity Compensation